Mobilization of hematopoietic stem cells with lenograstim in healthy donors: Efficacy and safety analysis according to donor age

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 5, 2015, Pages 881-888

  Martino, Massimo ^a   Bonizzoni, Erminio ^b   Moscato, Tiziana ^a   Recchia, Anna Grazia ^c   Fedele, Roberta ^a   Gallo, Giuseppe Alberto ^a   Console, Giuseppe ^a   Messina, Giuseppe ^a   Morabito, Fortunato ^c,d  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Biotechnology Research Unit   (Italy)

^d Azienda Ospedaliera Cosenza   (Italy)

Author keywords

Efficacy; G CSF; Healthy donors; Hematopoietic stem cells; Mobilization

Indexed keywords

CD34 ANTIGEN; LENOGRASTIM; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; RECOMBINANT PROTEIN;

ADULT; AGED; APHERESIS; ARTICLE; AUTOIMMUNE DISEASE; BODY WEIGHT; BONE PAIN; CARDIOVASCULAR DISEASE; FEMALE; FOLLOW UP; GROUPS BY AGE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HLA MATCHING; HUMAN; HUMAN CELL; MALE; SIBLING; SOLID TUMOR; STEM CELL MOBILIZATION; AGE; CYTOLOGY; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROCEDURES; RETROSPECTIVE STUDY; UNRELATED DONORS;

ADJUVANTS, IMMUNOLOGIC; AGE FACTORS; AGED; BLOOD COMPONENT REMOVAL; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; UNRELATED DONORS;

EID: 84928122126     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.01.021     Document Type: Article

References (52)

1. Passweg J.R., Baldomero H., Peters C., et al. Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. Bone Marrow Transplant 2014, 49:744-750.
2. Pasquini M., Wang Z., Horowitz M.M., et al. 2013 Report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. Clin Transplant 2013, 187-197.
3. Manton K.G., Corder L., Stallard E. Chronic disability trends in elderly United States populations: 1982-1994. Proc Natl Acad Sci U S A 1997, 94:2593-2598.
4. Artz A.S. Older patients/older donors: choosing wisely. Hematology Am Soc Hematol Educ Program 2013, 70-75.
5. Hurria A., Siccion E.P. Assessing the "fit" older patient for chemotherapy. Oncology (Williston Park) 2014, 28. 594, 596, 598-599.
6. Richa E.M., Kunnavakkam R., Godley L.A., et al. Assessing the 'fit' older patient for chemotherapy. Oncology 2014, 28(7). 594, 596, 598-599.
7. Sorror M.L., Sandmaier B.M., Storer B.E., et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA 2011, 306:1874-1883.
8. Bensinger W.I. Allogeneic transplantation: peripheral blood versus bone marrow. Curr Opin Oncol 2012, 24:191-196.
9. Machaczka M., Kalaitzakis E., Eleborg L., et al. Comparison of general vs regional anaesthesia for BM harvesting: a retrospective study of anaesthesia-related complications. Bone Marrow Transplant 2010, 45:53-61.
10. Buckner C.D., Clift R.A., Sanders J.E., et al. Marrow harvesting from normal donors. Blood 1984, 64:630-634.
11. Hosoya N., Miyagawa K., Mimura T., et al. Malignant hyperthermia induced by general anesthesia for bone marrow harvesting. Bone Marrow Transplant 1997, 19:509-511.
12. Favre G., Beksac M., Bacigalupo A., et al. Differences between graft product and donor side effects following bone marrow or stem cell donation. Bone Marrow Transplant 2003, 32:873-880.
13. Martino M., Fedele R., Massara E., et al. Long-term safety of granulocyte colony- stimulating factor in normal donors: is it all clear?. Expert Opin Biol Ther 2012, 12:609-621.
14. Schmitz N., Eapen M., Horowitz M.M., et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood 2006, 108:4288-4290.
15. Holtick U., Albrecht M., Chemnitz J.M., et al. Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. Cochrane Database Syst Rev 2014, (4):CD010189.
16. Kollman C., Howe C.W., Anasetti C., et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001, 98:2043-2051.
17. Vasu S., Leitman S.F., Tisdale J.F., et al. Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population. Blood 2008, 112:2092-2100.
18. Richa E., Papari M., Allen J., et al. Older age but not donor health impairs allogeneic granulocyte colony-stimulating factor (GCSF) peripheral blood stem cell mobilization. Biol Blood Marrow Transplant 2009, 15:1394-1399.
19. Suzuya H., Watanabe T., Nakagawa R., et al. Factors associated with granulocyte colony-stimulating factor-induced peripheral blood stem cell yield in healthy donors. Vox Sang 2005, 89:229-235.
20. De Lavallade H., Ladaique P., Lemarie C., et al. Older age does not influence allogeneic peripheral blood stem cell mobilization in a donor population of mostly white ethnic origin. Blood 2009, 113:1868-1869.
21. Siddiq S., Pamphilon D., Brunskill S., et al. Bone marrow harvest versus peripheral stem cell collection for haemopoietic stem cell donation in healthy donors. Cochrane Database Syst Rev 2009, (1):CD006406.
22. Bennett C., Evens A., Andritsos L., et al. Hematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol 2006, 135:642-650.
23. Confer L., Miller J. Long-term safety of filgrastim (rhGCSF) administration. Br J Haematol 2007, 137:77-78.
24. Pamphilon D., Nacheva E., Navarrete C., et al. The use of granulocyte colony-stimulating factor in volunteer unrelated hemopoietic stem cell donors. Transfusion 2008, 48:1495-1501.
25. Martino M., Console G., Dattola A., et al. Short and long-term safety of lenograstim administration in healthy peripheral haematopoietic progenitor cell donors: a single centre experience. Bone Marrow Transplant 2009, 44:163-168.
26. Hölig K., Kramer M., Kroschinsky F., et al. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. Blood 2009, 114:3757-3763.
27. Motlló C., Sancho J.M., Grífols J.R., et al. Mobilization and engraftment of peripheral blood stem cells in healthy related donors >55 years old. Cytotherapy 2014, 16:406-411.
28. Brando B., Barnett D., Janossy G., et al. Cytofluorometric methods for assessing absolute numbers of cell subsets in blood. Cytometry 2002, 42:327-346.
29. Keeney M., Brown W., Gratama J., et al. Single platform enumeration of viable CD34 pos cells. JBiol Regul Homeost Agents 2003, 17:247-253.
30. Martino M., Massara E., Irrera G., et al. Pulmonary micro-embolism in a healthy donor following G-CSF administration for mobilization of hemopoietic progenitor cells. Bone Marrow Transplant 2012, 47:308-310.
31. Sant M., Allemani C., Tereanu C., et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010, 116:3724-3734.
32. Gratwohl A., Schwendener A., Baldomero H., et al. Changes in use of hematopoietic stem cell transplantation; a model for diffusion of medical technology. Haematologica 2010, 95:637-643.
33. Gratwohl A., Baldomero H., Passweg J. Hematopoietic stem cell transplantation activity in Europe. Curr Opin Hematol 2013, 20:485-493.
34. Artz A., Ershler W.B. Hematopoietic cell transplantation in older adults. Practical geriatric oncology 2010, 262. Cambridge University Press, New York, NY. A. Hurtia, H.J. Cohen (Eds.).
35. Fischer J.C., Frick M., Wassmuth R., et al. Superior mobilisation of haematopoietic progenitor cells with glycosylated G-CSF in male but not female unrelated stem cell donors. Br J Haematol 2005, 130:740-746.
36. Ings S.J., Balsa C., Leverett D., et al. Peripheral blood stem cells yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used. Br J Haematol 2006, 134:517-525.
37. De La Rubia J., Arbona C., De Arriba F., et al. Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors. Transfusion 2002, 42:4-9.
38. Bertani G., Santoleri L., Martino M., et al. Identification of hematopoietic progenitor cell donor characteristics predicting successful mobilization: results of an Italian multicenter study. Transfusion 2014, 54:2028-2033.
39. Anderlini P., Donato M., Chan K.W., et al. Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience. Transfusion 1999, 39:555-560.
40. Al-Ali H.K., Bourgeois M., Krahl R., et al. The impact of age of HLA-identical siblings on mobilization and collection of PBSCs for allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2011, 46:1296-1302.
41. Lysák D., Kořístek Z., Gašová Z., et al. Efficacy and safety of peripheral blood stem cell collection in elderly donors: does age interfere?. JClin Apher 2011, 26:9.
42. Rinaldi C., Savignano C., Pasca S., et al. Efficacy and safety of peripheral blood stem cell mobilization and collection: a single-center experience in 190 allogeneic donors. Transfusion 2012, 52:2387-2394.
43. To L.B., Levesque J.P., Herbert K.E. How I treat patients who mobilize hematopoietic stem cells poorly. Blood 2011, 118:4530-4540.
44. Welch J.S., Ley T.J., Link D.C., et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012, 150:264-278.
45. Korbling M., Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter?. Blood 2001, 98:2900.
46. Navarro W.H., Switzer G.E., Pulsipher M. National marrow donor program session: donor issues. Biol Blood Marrow Transplant 2013, 19(1 Suppl.):S15-S19.
47. Pamphilon D., Siddiq S., Brunskill S., et al. Stem cell donation-what advice can be given to the donor?. Br J Haematol 2009, 147:71-76.
48. Olivieri A., Marchetti M., Lemoli R., et al. Proposed definition of "poor mobilizer" in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo. Bone Marrow Transplant 2012, 47:342-351.
49. Pierelli L., Perseghin P., Marchetti M., et al. Best practice for peripheral blood progenitor cell mobilization and collection in adults and children: results of a Società Italiana Di Emaferesi e Manipolazione Cellulare (SIDEM) and Gruppo Italiano Trapianto Midollo Osseo (GITMO) consensus process. Transfusion 2012, 52:893-905.
50. World Cancer Report. 2014 Online (EPUB) version.
51. Nichols M., Townsend N., Luengo-Fernandez R., et al. European Cardiovascular Disease Statistics 2012 2012, European Heart Network, European Society of Cardiology, Sophis Antipolis, Brussels, http://www.escardio.org/about/Documents/EU-cardiovascular-disease-statistics-2012.pdf.
52. Cooper G.S., Stroehla B.C. The epidemiology of autoimmune diseases. Autoimmun Rev 2003, 2(3):119-125.